The Case for Adaptive Radiotherapy
View the first Radiotherapy Impact
Report featuring Adaptive Radiotherapy
Redefining Precision
The Case for Adaptive Radiotherapy
Every minute, approximately 38 people worldwide receive a cancer diagnosis, and 19 lose their lives to the disease.1 With one in every five people expected to develop cancer in their lifetime, nearly everyone is touched by its impact — whether as a patient, survivor, caregiver, or loved one. This year alone, cancer is projected to cause 10 million deaths.
Radiation therapy is one of the most powerful tools to confront this global burden. More than half of all cancer patients will receive radiation during their treatment journey.2 Yet despite its central role, traditional radiotherapy has faced a persistent limitation: the human body is not static. Tumors shrink or shift, organs move with breathing or digestion, and anatomy can vary from one session to the next.
To manage these uncertainties, clinicians have historically expanded treatment margins, the extra area of tissue included around the visible tumor in the radiation field — ensuring the tumor receives adequate dose, but often at the cost of exposing more healthy tissue. This balance between precision and safety has defined radiotherapy for decades.
Radiotherapy Reinvented
Adapting to Patients for Better Care
Adaptive Radiotherapy changes that equation. By combining high-quality imaging with AI-driven planning and automation, Adaptive Radiotherapy allows clinicians to adjust treatment plans in near real time. Rather than relying on a single, static plan, radiation delivery can evolve daily or weekly to reflect each patient’s unique anatomy at the time of treatment.
The Adaptive Radiotherapy advantage: by adapting to daily or weekly plans with advanced imaging, Adaptive Radiotherapy ensures precise dosing while reducing exposure to healthy tissue.
Explore the Research
View Key StudiesAdaptive Radiotherapy
A New Standard of Care in Radiation Oncology
Beyond the clinical benefits, Adaptive Radiotherapy represents a fundamental shift in radiation oncology. It enables personalized treatment at scale — aligning radiation delivery with the reality of each patient’s anatomy and tumor biology.
The case for Adaptive Radiotherapy is clear: it is not just an innovation, but a step toward redefining radiotherapy as a dynamic, adaptive process that offers patients the best chance of treatment success.
For patients
More effective therapy with fewer side effects.
For clinicians, administrators, and researchers
A pathway to advance precision medicine, strengthen operational efficiency, and contribute to the growing body of evidence shaping the future standards of cancer care.
Ready to Get Started?
Contact usReferences
- Calculated based on 10 million deaths/year in.
- RT and theranostics: a Lancet Oncology Commission, May Abdel-Wahab, Francesco Giammarile, Mauro Carrara, Diana Paez, Hedvig Hricak, Nayyereh Ayati, et al. 2024 September, The Lancet Oncology Vol. 25 No. 11 e545-e580